BASP1 interacts with estrogen receptor α and modifies the tamoxifen response

Lindsey Marsh, Samantha Carrera, Jayasha Shandilya, Kate Heesom, Andrew Davidson, K F Medler, Stefan Roberts

Research output: Contribution to journalArticle (Academic Journal)peer-review

20 Citations (Scopus)
288 Downloads (Pure)


Tamoxifen binds to estrogen receptor α (ERα) to elicit distinct responses that vary by cell/tissue type and status, but the factors that determine these differential effects are unknown. Here we report that the transcriptional corepressor BASP1 interacts with ERα and in breast cancer cells, this interaction is enhanced by tamoxifen. We find that BASP1 acts as a major selectivity factor in the transcriptional response of breast cancer cells to tamoxifen. 40% of the genes that are regulated by tamoxifen in breast cancer cells are BASP1-dependent, including several genes that are associated with tamoxifen resistance. BASP1 elicits tumour-suppressor activity in breast cancer cells and enhances the anti-tumourigenic effects of tamoxifen treatment. Moreover, BASP1 is expressed in breast cancer tissue and is associated with increased patient survival. Our data has identified BASP1 as an ERα cofactor that plays a central role in the transcriptional and anti-tumourigenic effects of tamoxifen.
Original languageEnglish
Article numbere2771
Number of pages10
JournalCell Death and Disease
Issue number5
Publication statusPublished - 11 May 2017


  • BASP1
  • Estrogen receptor
  • ERα
  • Tamoxifen
  • Breast cancer
  • Transcription


Dive into the research topics of 'BASP1 interacts with estrogen receptor α and modifies the tamoxifen response'. Together they form a unique fingerprint.

Cite this